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KEY POINTS 
1) Performance of HbA1c analyzers is, on the whole, very good with many attaining the international guidance target of sigma 
>2 at a TAE of 10%, in addition many analysers perform well in excess of these targets, as individual analyzers or in 
networks of analysers across a wide geographical area 
2) In strict evaluation conditions, point of care test devices can perform as well as routine laboratory analysers and may in 
future be considered suitable for use in the diagnosis of diabetes 
3) Using direct calibration to the primary reference measurement procedure we have demonstrated that there is the capacity 
to improve performance of analysers in routine clinical practice  
4) Whilst fewer analysers currently meet tighter targets of a TAE of 10% and four sigma and TAE of 6% at two sigma, the 
outcomes for pass or fail are comparable for the two criteria. 
5) Precision has a greater impact on the calculated sigma than bias does, in the current data set. There are many ways in 
which to calculate bias and imprecision and the method used to establish these values must be detailed in any evaluation or 
study. 
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This study utilizes three unique data sets to demonstrate the state of the art of HbA1c analyzers in a range of settings and compares 
their performance against the international guidance set by the IFCC task force for HbA1c standardization. The data is used to 
demonstrate the effect of tightening of those criteria and the study serves as a guide to the practical implementation of the sigma 
metrics approach in a range of clinical settings.  
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Introduction 
 
Global standardization of HbA1c methods, in particular through the International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) primary reference method, has been the fore-runner to a 
marked improvement in the analytical performance of many HbA1c assays. The IFCC primary 
reference method has been proven to be stable in many inter-comparison studies with designated 
comparison methods (DCMs), (the NGSP and the Japanese Diabetes Society (JDS)/Japanese 
Society of Clinical Chemistry (JSCC)), method and is recognized in a 2010 consensus statement as 
the only valid anchor for the standardization of HbA1c (1, 2). The development of this reference 
method enabled the World Health Organization (WHO) and American Diabetes Association (ADA) to 
advocate the use of HbA1c for the diagnosis of type two diabetes (3). WHO guidance stipulates that 
“stringent quality assurance tests are in place and assays are standardized to criteria aligned to the 
international reference values”. In addition to standardization, it is imperative that tests used for the 
diagnosis of diabetes meet strict analytical performance criteria as both bias and imprecision have the 
potential to affect reported values. This effect may be to the extent to cause mis-classification of a 
patient’s result, and thus give rise to either an inappropriate positive diagnosis or a missed diagnosis.  
In 2015 the IFCC Task Force on Implementation of HbA1c Standardization published an investigation 
of two different models to set and evaluate quality targets for HbA1c (4). The biological variation 
model and sigma-metrics model were investigated. The IFCC Task force advocates the use of the 
sigma-metric model, as the model of choice, as the within biological variation of HbA1c is very small 
and analytical performance criteria derived from biological variation of HbA1c are too strict even for 
the best performing HbA1c methods currently on the market (5). The taskforce set out guidance for 
the application of the sigma metrics model for HbA1c in all countries with the purpose of engaging 
international stakeholders in the field of diabetes to further the development of analytical quality at a 
global level. 
In the laboratory sigma-metrics is a quality management strategy that provides a universal 
benchmark for process performances. Sigma-metrics places analytical characteristics (bias and 
imprecision) in the form of Total Allowable Error (TAE) within a framework of clinical requirements. 
Sigma Metrics allows the user to define the TAE they wish to achieve and how often results can 
acceptably be outside of this target value. The higher the sigma unit, the fewer times a system is 
allowed to fall short of the required target. A sigma of two implies a 5% risk to fail the TAE, i.e. it is 
acceptable for 5% of results to not meet the TAE value that has been pre-set. TAE for HbA1c has 
been set by the IFCC Task Force on Implementation of HbA1c standardization as a default of 5 
mmol/mol (0.46% DCCT) at an HbA1c level of 50 mmol/mol (6.7% DCCT) which corresponds with a 
relative TAE of 10% ((5/50)*100%) in SI units (6.9% DCCT units ((0.46/6.7)*100%)) (6). 
The aim of this study was to explore the ways in which sigma metrics is applied in clinical laboratory 
testing using the criteria set by the IFCC Task Force. Three approaches were used as exemplars of 
range of different uses of the sigma metrics approach. These were:  
1) data from an EQA program of 134 individual laboratories in the Netherlands using a variety HbA1c 
methods, demonstrating how sigma is used in ‘real-life’ routine settings  (6) 
2) data from a recent evaluation of the performance of 7 HbA1c POC instruments to calculate sigma, 
which demonstrates how sigma metrics can be used to evaluate new or existing instruments at a 
laboratory level (7). 
3) data from the IFCC monitoring program  from  6 certified  secondary reference method procedures 
(SRMP) to the IFCC reference method procedure (RMP) to calculate sigma , demonstrating how well 
methods perform at higher order levels (8).    
In addition, changing the TAE of 10% to 6% in SI units was investigated to indicate the potential 
impact of tightening the criteria in the future. 
 
 
Methods 
 
Part One) Data from the recent (2016.2) Stichting Kwaliteitsbewaking Medische Laboratoria (SKML) 
External Quality Assurance Services (EQAS) in the Netherlands were used to assess the individual 
laboratory performance of various HbA1c methods using sigma-metrics (6). In the SKML EQA 
program four fresh whole blood EDTA samples are distributed to individual laboratories, six times per 
year. The samples should to be analyzed within forty-eight hours of receipt and the results are 
submitted to the website of SKML. The results of the latest survey were used to calculate sigma. The 
target values of the distributed samples were assigned with the following six IFCC certified secondary 
reference measurement procedures (SRMP) based at two European reference laboratories, with 
values determined on two individual days in duplicate (9): 
European Reference Laboratory for Glycohemoglobin, location Isala, Zwolle, The Netherlands:  
 Roche Tina-quant Gen.2 HbA1c on Integra 800, immunoassay, (Roche Diagnostics); 
 Premier Hb9210, boronate affinity chromatography HPLC, (Trinity Biotech);  
 Tosoh G8, cation-exchange HPLC, (Tosoh Bioscience). 
European Reference Laboratory for Glycohemoglobin, location Queen Beatrix Hospital, Winterswijk, 
The Netherlands: 
 Sebia Capillarys 2 Flex Piercing, capillary electrophoresis, (Sebia); 
 Premier Hb9210, boronate affinity chromatography HPLC,  (Trinity Biotech); 
 Menarini HA8180, cation-exchange HPLC, (Menarini Diagnostics).  
The six SRMP were all calibrated with IFCC secondary reference material and showed excellent 
performance in the IFCC monitoring program 2015.  
The mean of the four samples minus the mean of the target value set by the six SRMPs was used to 
calculate  bias. The within-laboratory SD was calculated from the residual SD regression line through 
the laboratory results versus the target values and was used to calculate the coefficient of variation 
(CV) (10). Sigma was calculated with the formula: σ=(TAE – B)/CV where TAE is total Allowable 
Error, B is bias compared to a reference method and CV is imprecision of the method. The TAE used 
was 5 mmol/mol (0.46% DCCT) at an HbA1c level of 50 mmol/mol (6.7% DCCT) which corresponds 
with a relative TAE of 10% ((5/50)*100%) in SI units (6.9% DCCT units ((0.46/6.7)*100%)) (4). 
Part two) Data from an evaluation study of seven HbA1c point-of-care instruments done in our lab in 
2014 (7) and the latest results of an evaluation of the Quo-Test after the manufacturer claimed to 
have adjusted the calibration are included. In these studies the CLSI EP-5 and EP-9 protocols were 
used to establish precision and accuracy (bias) for the POCT instruments. The CLSI EP-9 protocol 
was performed twice, with two different reagent lot numbers, and the bias was determined between 
the POC instruments and the mean of the first three SRMPs detailed above. The sigma value was 
calculated three different ways using the CV, of a sample with an HbA1c value of approximately 48 
mmol/mol (6.5% DCCT), established in the EP-5 protocol and the CVs calculated from the duplicates 
in the EP-9 protocol using two different lot numbers. The bias was calculated at 48 mmol/mol using, 
Deming regression analysis compared to the mean of the first three SRMPs. 
Part three) The design of the IFCC monitoring program is based on twenty four interconnected EDTA 
whole blood samples. The samples are sent annually to IFCC certified reference labs and 
subsequently stored at or below -70°C. One sample is then analyzed every fortnight, and the results 
are to be submitted to the website of HbA1c/IFCC (8). The twenty four samples are in fact twelve 
blinded samples in duplicate. From these duplicates the CV was calculated. Values of samples were 
assigned by the whole IFCC network (eighteen approved IFCC primary reference laboratories) each 
running the IFCC primary reference method (9). Data from the 2015 monitoring program were used to 
calculate the performance of six IFCC SRMPs mentioned above in part one. 
In addition to the above, data was reanalyzed to investigate the impact of changing targets from a 
TAE of 10% to a TAE 6% to elucidate the likely impact of ‘tightening’ the performance criteria. The 
pass and fail rate calculated with a TAE of 10% and four sigma was compared with the pass and fail 
rate with a TAE of 6% and a two sigma. 
 
Statistics 
 
Calculations were performed using Microsoft® Excel 2010 (Microsoft Corporation). Statistical analyses 
were performed using Analyse-It® (Analyse-It Software) and EP Evaluator Release 9 (Data 
Innovations LLC) (11). 
For the duplicates in the EP-9 protocol and in the IFCC monitoring program, CV was calculated with 
the following formula: 
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where CVa is the analytical CV, ∆ is the difference between duplicates, n is the number of duplicates, 
and x  is the mean of the duplicates. 
 
Results 
Part One) Of the 134 laboratories who participated in the SKML-EQAS in the Netherlands, 90.3%, of 
the methods used in these laboratories, met the criteria of having σ >2, and 74.6% actually met 
standards for σ >4 with a TAE of 10%. With a TAE of 6%, 70.1% met the criteria for σ >2 and 41.0 % 
for σ >4 (Table 1 and Figure 1A and 1B). As an example, the Menarini HA8180 in one laboratory, had 
a calculated sigma of 32.7 due to a CV of 0.30% and a bias of 0.2%. Using the formula: σ=(TAE – 
B)/CV resulted in a calculated sigma value of 32.7 ((10-0.2)/0.30=32.7). A very high sigma is 
generated with a low CV, generally below 1%. The opposite effect is also possible. A bias greater 
than the TAE of 10% will result in a negative sigma value. In practice a sigma of 32.7 is essentially 
equal to a sigma of 6 because world class performance is world class performance no matter how 
high the calculated sigma. A negative sigma indicates that the method fails to meet the set criteria 
more often than it achieves these set criteria. Table 1 details the range of sigma values that were 
calculated for each method, representing the distribution of the performance of that particular method 
between laboratories. However, this is better shown in Figure 1A. Most of the methods cluster around 
a certain sigma, except for the Roche method group, which shows the widest range of sigma values 
amongst users. Figure 1C compares the distribution of performance when using the alternative 
criteria of either a TAE of 10% and 4 sigma or a TAE of 6% and 2 sigma as criteria. Fewer individual 
laboratories would meet the criteria if the TAE was reduced than if the sigma target was increased. 
 
Part two) Table 2 shows the results of the sigma calculations using data from a previous POCT 
evaluation study.  All POCT methods, except the first evaluations of the Quo-Lab and the Quo-Test, 
had a sigma > 2 (TAE 10%) and this was independent of which CV was used (EP-5 or CV from 
duplicates in EP-9 lot number A or B). Only the B-analyst had a sigma >4 with TAE of 10% and sigma 
> two with a TAE of 6%. Table 2 and Figure 2A show that a method can pass the criteria of having a 
sigma >2 with TAE of 10% even if the bias is 5.7% and 6% (InnovaStar) due to a very low CV (1.9, 
1.4 and 0.9%). Taking a TAE of 6% and two sigma as the criteria, this method would have failed 
(Figure 2B), as would the DCA Vantage and, potentially, the Afinion analysers. Figure 2C shows that 
the pass and fail rate for the POCT methods when using criteria of TAE of 10% and four sigma was 
almost equal to a TAE of 6% and two sigma.  
 
Part three) Table 3 shows the current criteria of the IFCC monitoring program. The six SRMP 
evaluated showed excellent performance in 2015 concerning deviation from IFCC target, 
reproducibility and linearity. High sigma values were calculated at HbA1c values of 30, 60 and 90 
mmol/mol, which are the levels at which deviation from IFCC target values are detailed on the annual 
monitoring certificate (Table 4). Again it can be seen from Table 4 that a CV <1.0% leads to sigma 
values > 6 (Tosoh G8 and Menarini HA8180).  Figure 3A shows the results of the six SRMP using the 
bias at 60 mmol/mol and a TAE of 10% and Figure 3B shows the same results but with a TAE of 6%. 
All SRMP had a sigma > four with a TAE of 10% and a sigma > two with a TAE of 6% (Figure 3C).  
 
Discussion 
The global context This study used data from three different clinical settings in order to highlight the 
current state of the art of HbA1c analyzers that are in routine use around the world. The TAE of 10% 
(5 mmol/mol at an HbA1c value of 50 mmol/mol) was set as a default by the IFCC Task force and 
these goals should serve as a starting point for discussion with international stakeholders in the field 
of diabetes. This cut-point was chosen as it is based on the difference in HbA1c results, in two 
consecutive HbA1c tests that clinicians use as a guide to change therapy and is therefore a clinical 
decision limit (4). Previous guidance focused on the imprecision of methods with instruments 
expected to perform at a within laboratory CV of <3% for SI units and <2% for % (NGSP) units. The 
sigma metrics approach allows for both bias and imprecision to be taken into account when 
assessing analytical performance, generating a more comprehensive view of performance.  
Performance within and between countries Results from part one of this study clearly show that 
the vast majority of individual laboratories (90%) are meeting these targets of a sigma value of >2 at a 
TAE <10%. Two method groups (Roche and Bio-Rad) performed less well with a wide range of sigma 
values calculated for the within method group. A reason for this large distribution might be that in this 
EQA program the Roche method was taken as one group (whole blood application and hemolysate 
application, Gen. 2 and Gen. 3 reagent, using different instruments (Cobas Integra 800, Cobas 
C8000, Hitachi), giving considerable heterogeneity to the group. In addition, as with all methods 
factors such as technical/analytical skills required to perform the analysis and maintenance of 
instrument etc can have an impact on performance and thus sigma values. In general one can say 
that the smaller the distribution (range) of sigma values the more robust and reproducible that 
particular method is likely to be at that sigma level. 
It is difficult to draw conclusions for some method groups due to small user numbers, however it can 
be seen that increasing the sigma cut point to >4 sigma leads to a reduction in the number of 
laboratories meeting that target (80%). This falls further to 75% with a TAE of 6% and sigma of >2.  
Individual laboratories or networks of laboratories in any country can use the results of their EQA data 
to calculate their bias and imprecision and use this model to assess the performance of their own 
analyzer(s). The minimum expected standard is a sigma value of 2 or greater at a TAE of 10%. 
 
How do POC devices compare? Part two data shows that, under strict evaluation conditions, most 
POCT devices perform to the same limits that are expected of laboratory analyzers. Only the Quo-
Lab and Quo-Test did not reach these targets, however the Quo-Test did meet the targets after a 
manufacturer re-calibration. This is a significant finding as the question as to whether or not POC 
devices can be used for the diagnosis of diabetes is regularly raised. These findings would indicate 
that the majority of methods could be used in this setting however, it should be cautioned that the 
performance demonstrated here may not reflect the performance of these devices in the clinical 
setting, with multiple users and multiple lot numbers and further evidence is required before 
advocating the use of POCT devices for the diagnosis of diabetes. Indeed when the criteria are 
tightened to 4 sigma at a TAE of 10%, only one analyzer demonstrated a consistent ability to meet 
that target and with a reduced TAE of 6% and 2 sigma, only two instruments met the targets, 
indicating that at TAE of 10% at 2 sigma is the current state of the art of these analyzers. 
 Establishing the limit of performance of routing analyzers Part three data demonstrates how well 
routine laboratory analyzers can perform when directly calibrated to the IFCC RMP. Each of the six 
SRMPs performed exceptionally well meeting both the sigma >2 and sigma >4 targets at a TAE of 
10%, in addition all also met the sigma >2 at a TAE of 6% target. This shows that routine analyzers 
have the capacity to meet these stringent performance targets and the aim should be to increase 
performance to these levels, in the clinical setting. 
 
Future aims Overall, the performance of the majority of laboratory and POC analyzers for HbA1c is 
very good. Whilst not all analyzers are currently meeting the proposed target of >2 sigma at a TAE of 
10%, some analyzers are already performing far in excess of this target, clearly indicating the 
capacity for excellent performance in routine clinical settings. Manufacturers and users of all 
instruments should strive to further improve the quality and consistency of the results they produce, to 
ensure that 100% of methods meet the basic quality targets. Once this has been achieved then the 
criteria can be further tightened, this will allow HbA1c analysis to become the benchmark for 
performance of all laboratory testing. It should be noted that the IFCC task force also advocated the 
use of analyzers that perform to the level of four sigma with a TAE of 10% when used for clinical 
trials, this is achievable with a range of current analyzers, but not all and care should be taken when 
selecting and instrument to be used for collecting trial data. 
 
Should the performance guidelines but changed? This study also evaluated the impact of 
tightening the performance criteria to >4 sigma at 10% TAE or >2 sigma at 6% TAE. Both targets 
produced similar findings with slightly fewer methods attaining the latter target. Whilst increasing the 
sigma level will still allow some methods to pass with a considerable bias it could be used to give the 
clinician the confidence to know that the result they have is true, within a specific range, and it is very 
unlikely that the value is ever likely to be outside of that range. However decreasing the TAE means 
that the range of values around the true value will be much smaller, with the caveat that up to 5% of 
results will not fall in that range. For the clinician this does leave some uncertainty as they would not 
know which results were outside of the expected range, however for a situation where minimum 
deviation from the true value is required then this would be the preferred choice.  
The primary focus for the immediate future should be to ensure that all analyzers perform to the 
minimum standards set by the IFCC task force and this performance should be considered when 
deciding on which analyzer to choose, once this goal is achieved further tightening of the criteria can 
be discussed.  
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